RT Journal Article
SR Electronic
T1 Single versus Combination Treatment in Tinnitus: An International, Multicentre, Parallel-arm, Superiority, Randomised Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.09.24300978
DO 10.1101/2024.01.09.24300978
A1 Schoisswohl, Stefan
A1 Basso, Laura
A1 Simoes, Jorge
A1 Engelke, Milena
A1 Langguth, Berthold
A1 Mazurek, Birgit
A1 Lopez-Escamez, Jose Antonio
A1 Kikidis, Dimitrios
A1 Cima, Rilana
A1 Bernal-Robledano, Alberto
A1 Boecking, Benjamin
A1 Bulla, Jan
A1 Cederroth, Christopher R.
A1 Crump, Holger
A1 Denys, Sam
A1 Escalera-Balsera, Alba
A1 Gallego-Martinez, Alvaro
A1 Gallus, Silvano
A1 Goedhart, Hazel
A1 Hidalgo-Lopez, Leyre
A1 Jarach, Carlotta M.
A1 Kader, Hafez
A1 Koller, Michael
A1 Lugo, Alessandra
A1 Marcrum, Steven C.
A1 Markatos, Nikos
A1 Martin-Lagos, Juan
A1 Martinez-Martinez, Marta
A1 Muller-Locatelli, Nicolas
A1 Neff, Patrick
A1 Niemann, Uli
A1 Perez-Carpena, Patricia
A1 Pryss, Rüdiger
A1 Puga, Clara
A1 Robles-Bolivar, Paula
A1 Rose, Matthias
A1 Schecklmann, Martin
A1 Schiele, Tabea
A1 Schleicher, Miro
A1 Schobel, Johannes
A1 Spiliopoulou, Myra
A1 Stark, Sabine
A1 Staudinger, Susanne
A1 Stege, Alexandra
A1 Toedtli, Beat
A1 Trochidis, Ilias
A1 Unnikrishnan, Vishnu
A1 Vassou, Evgenia
A1 Verhaert, Nicolas
A1 Vogel, Carsten
A1 Zachou, Zoi
A1 Schlee, Winfried
YR 2024
UL http://medrxiv.org/content/early/2024/08/13/2024.01.09.24300978.abstract
AB Tinnitus is associated with a variety of aetiologies, phenotypes, and underlying pathophysiological mechanisms, and available treatments have limited efficacy. A combination of treatments, addressing various aspects of tinnitus, might provide a viable and superior treatment strategy.In this international multicentre, parallel-arm, superiority, randomised controlled trial, patients with chronic subjective tinnitus were recruited from five clinical sites across the EU as part of the interdisciplinary collaborative UNITI project. Patients were randomly assigned using a web-based system, stratified by their hearing and distress level, to single or combination treatment of 12 weeks. Cognitive-behavioural therapy, hearing aids, structured counselling, and sound therapy were administered either alone or as a combination of two treatments resulting in ten treatment arms. The primary outcome was the difference in the change from baseline to week 12 in the total score of the Tinnitus Handicap Inventory (THI) between single and combination treatments in the intention-to-treat population. All statistical analysis were performed blinded to treatment allocation.674 patients of both sexes aged between 18 and 80 years were screened for eligibility. 461 participants (190 females) with chronic subjective tinnitus and at least mild tinnitus handicap were enrolled, 230 of which were randomly assigned to single and 231 to combination treatment. Least-squares mean changes from baseline to week 12 were -11.7 for single treatment (95% confidence interval [CI], -14.4 to -9.0) and -14.9 for combination treatments (95% CI, -17.7 to -12.1), with a statistically significant group difference (p=0.034). Cognitive-behavioural therapy and hearing aids alone had large effect sizes, which could not be further increased by combination treatment. No serious adverse events occurred.In this trial involving patients with chronic tinnitus, all treatment arms showed improvement in THI scores from baseline to week 12. Combination treatments showed a stronger clinical effect than single treatment, however, no clear synergistic effect was observed when combining treatments. We observed rather a compensatory effect, where a more effective treatment offsets the clinical effects of a less effective treatment.ClinicalTrials.gov Identifier: NCT04663828.Competing Interest StatementDetails on competing interest can be found in the preprint.Clinical TrialNCT04663828Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05835-z https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07303-2 Funding StatementThis clinical trial received funding from the European Unions Horizon 2020 Research and Innovation Program (grant agreement number 848261)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was independently approved by the following ethics committees: University of Regensburg, Regensburg, Germany (combined ethical approval for clinical sites Berlin and Regensburg); Katholieke Universiteit Leuven, Leuven, Belgium; Ethniko Kai Kapodistriako Panepistimo Athinon, Athens, Greece; Hospital Universitario Virgen de las Nieves/ Hospital Clinico Universitario San Cecilio, Granada, Spain.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDe-identified data generated from this trial will initially be available only on request for researchers to reproduce results, later publicly via ZENODO. Current data availability will be reported on the UNITI website (https://uniti.tinnitusresearch.net/).